Wenming Chen

Dr. Wenming Chen


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2014 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
CGChuanying Geng
Chuanying Geng
JHJian Hou
Jian Hou
YZYaozhong Zhao
Yaozhong Zhao
XKXiaoyan Ke
Xiaoyan Ke
ZWZhao Wang
Zhao Wang
Wenming ChenWenming Chen
Wenming Chen

1 May 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YHYing Hu
Ying Hu
Wenming ChenWenming Chen
Wenming Chen
JWJingbo Wang
Jingbo Wang
Sequencing studies have been used to determine a spectrum of multiple myeloma (MM) mutations. Mutation of certain genes, including KRAS, NRAS, TP53, FAM46C, DIS3 and BRAF, have a high recurrence rate and may play important roles in the pathogenesis, progression and prognosis of MM. Mutations in DIS3, which encodes a highly conserved RNA exonuclease, lead to loss of function. The expression of FAM46C is highly correlated with the expression of ribosomal protein, but the exact function of FAM46C mutation is unclear. There are mutants of IRF4, which is considered an MM survival factor. Mutations in the gene coding for the DNA damage-binding protein (DDB1) may affect interactions with CUL4A, which is part of the cereblon (CRBN) ubiquitin ligase complex. IRF4is part of the complex, which binds to DNA. These findings might explain the resistance to immunomodulatory. TP53 deletion or mutation is often present in B-cell malignancies and is associated with low response rates. Myeloma pathogenic mutations in ATM have been found in adult lymphatic tumors. XBP1 and PSMB5 mutations may be related to bortezomib resistance. Multiple gene mutations (KRAS, NRAS and BRAF) involved in the same pathway were found a single patient. Identification of driver gene mutations has brought great hope to the field of individualized, targeted medicine for MM.

10 March 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
XWXiaoxiao Wu
Xiaoxiao Wu
JGJianying Guo
Jianying Guo
YCYuling Chen
Yuling Chen
XLXiaohui Liu
Xiaohui Liu
GYGuangzhong Yang
Guangzhong Yang
Wenming ChenWenming Chen
Wenming Chen

14 December 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZZZhiyao Zhang
Zhiyao Zhang
YLYan-Chen Li
Yan-Chen Li
CGChuan-Ying Geng
Chuan-Ying Geng
HWHui-Juan Wang
Hui-Juan Wang
Wenming ChenWenming Chen
Wenming Chen
This study evaluated the potential relationship between exosomal miRNAs and clinical symptoms in patients with multiple myeloma (MM). Forty-eight newly diagnosed myeloma patients and sixteen normal donors were enrolled in the study. The results showed that the relative expression levels of let-7c-5p, let-7d-5p, miR-140-3p, miR-185-5p, and miR-425-5p in the exosomes of MM patients were significantly lower than those of healthy controls. Furthermore, there were significant differences in the clinical characteristics of myeloma, such as kidney damage, while the expression levels of the same miRNA in exosomes and serum are not correlated. The expression of exosomal miRNA is related to the expression levels of clinical feature-related factors, such as creatinine, β2-microglobulin, β-CTX, and IL-6 in serum. Establishing this relationship could contribute to understanding the pathogenesis of MM.

12 May 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YLYun Leng
Yun Leng
JHJian Hou
Jian Hou
JJJie Jin
Jie Jin
MZMei Zhang
Mei Zhang
XKXiaoyan Ke
Xiaoyan Ke
Wenming ChenWenming Chen
Wenming Chen

1 May 2016 in Medicine
Verified
Journal Article
Open access
YJYuan Jian
Yuan Jian
XCXiaolei Chen
Xiaolei Chen
HZHuixing Zhou
Huixing Zhou
WZWanqiu Zhu
Wanqiu Zhu
NLNian Liu
Nian Liu
Wenming ChenWenming Chen
Wenming Chen
The identification of specific cytogenetic abnormalities by interphase fluorescence in situ hybridization (i-FISH) has become a routine procedure for prognostic stratification of multiple myeloma (MM) patients. In this study, the prognostic significance of cytogenetic abnormalities detected by interphase fluorescence in situ hybridization (iFISH) in 229 newly diagnosed multiple myeloma patients was retrospectively analyzed. Results showed that del (17p), t(4;14), and 1q21 gain were adverse predictors of progression-free survival (PFS). Patients who carried these cytogenetic abnormalities were more likely to have more adverse biological parameters and lower response rate. Multivariate analysis showed that del (17p), t(4;14), and 1q21 gain were statistically independent predictors of PFS, whereas del (17p) was also adverse predictor of overall survival. Multiple coexisting cytogenetic abnormalities also had a negative correlation with PFS. Bortezomib-based therapy could improve the rate and depth of response in patients with t(4;14) translocation and 1q21 gain. Autologous stem cell transplantation could improve, but not overcome the adverse prognostic effect of high-risk cytogenetic abnormalities. These results demonstrate that MM patients with iFISH abnormalities, especially del (17p), are more likely to have a poor prognosis.